Clinical Research Directory
Browse clinical research sites, groups, and studies.
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor: PanTher Therapeutics
Summary
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Official title: A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
26
Start Date
2025-04-14
Completion Date
2028-06
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
PTM-101
PTM-101, an absorbable drug product containing paclitaxel
Locations (6)
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Northwell Health Zuckerberg Cancer Center
Lake Success, New York, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Virginia Mason Medical Center
Seattle, Washington, United States